Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nektar Therapeutics
(NQ:
NKTR
)
1.320
-0.030 (-2.22%)
Official Closing Price
Updated: 4:15 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Nektar Therapeutics
< Previous
1
2
3
4
5
Next >
68 Biggest Movers From Yesterday
April 19, 2022
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core...
Via
Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide
April 18, 2022
U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday.
Via
Benzinga
Expert Ratings for Nektar Therapeutics
April 18, 2022
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why is Nektar Therapeutics (NKTR) Stock Down Today?
March 14, 2022
Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock?
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
April 18, 2022
Gainers Natus Medical (NASDAQ:NTUS) shares rose 28.8% to $33.55 during Monday's regular session. The current volume of 3.0 million shares is 2073.2% of Natus Medical...
Via
Benzinga
Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views
April 18, 2022
U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.
Via
Benzinga
34 Stocks Moving In Monday's Mid-Day Session
April 18, 2022
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions....
Via
Benzinga
Why Nektar Shares Are Down Almost 35%
April 18, 2022
Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in...
Via
Benzinga
Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points
April 18, 2022
U.S. stocks traded higher this morning, with the Dow Jones adding around 100 points on Monday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
April 18, 2022
Upgrades
Via
Benzinga
Benzinga's Daily Brief On Trending Tickers For April 18, 2022: Casa Systems, Twitter, DiDi Global, And More
April 18, 2022
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 18, 2022
Gainers Natus Medical (NASDAQ:NTUS) stock rose 28.3% to $33.42 during Monday's pre-market session. The market value of their outstanding shares is at $1.1 billion....
Via
Benzinga
Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program
April 18, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
April 14, 2022
Gainers
Via
Benzinga
Best Performers Since 3/14 Pivot
March 22, 2022
Early last week, the US equity market pivoted, gaining 1%+ for four consecutive days between last Tuesday and last Friday. Sentiment has shifted amongst the investing community for the time being.
Via
Talk Markets
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
March 20, 2022
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Nektar Therapeutics
March 15, 2022
Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Where Nektar Therapeutics Stands With Analysts
March 15, 2022
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
March 15, 2022
Wells Fargo cut the price target on Coupa Software Incorporated (NYSE: LPI) from $190 to $80. Laredo Petroleum shares fell 29.8% to $63.10 in pre-market trading.
Via
Benzinga
Mid-Afternoon Market Update: Dow Turns Negative; Turquoise Hill Resources Shares Spike Higher
March 14, 2022
U.S. stocks turned lower toward the end of trading on Monday as the Dow Jones dropped 100 points, after surging more than 400 points earlier during the session. The Dow...
Via
Benzinga
96 Biggest Movers From Yesterday
March 15, 2022
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share. Incannex...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 14, 2022
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 48.0% to $20.95 during Monday's regular session. The company's market cap stands at $1.0 billion....
Via
Benzinga
Knightscope News: Why Is KSCP Stock Up Today?
March 14, 2022
Knightscope (KSCP) stock is on the move Monday following news that the company signed onto a new real estate development project.
Via
InvestorPlace
Mid-Day Market Update: Markets Mixed; Nasdaq Drops Over 100 Points
March 14, 2022
The Nasdaq index turned lower midway through trading, losing more than 100 points on Monday. The Dow traded up 0.61% to 33,143.88 while the NASDAQ fell 1.13% to 12,698.26....
Via
Benzinga
Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit
March 14, 2022
Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of...
Via
Benzinga
Mid-Morning Market Update: Markets Open Higher; Crude Oil Dips 8%
March 14, 2022
U.S. stocks opened on a strong note this morning, with the Dow Jones gaining 300 points on Monday. Following the market opening Monday, the Dow traded up 0.99% to 33,269.95 while...
Via
Benzinga
50 Stocks Moving In Monday's Mid-Day Session
March 14, 2022
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share. AgriFORCE Growing Systems,...
Via
Benzinga
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops
March 14, 2022
Sentiment was low heading into the study and analysts aren't hopeful for other tests.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2022
March 14, 2022
Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter,...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.